FindTrial
Sign In

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07332338
Enrollment
Unknown
Registered
2026-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral, Long COVID, Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome

Keywords

Long COVID, Post-COVID syndrome, Post-COVID condition, Umbilical cord blood, REGENECYTE, Post-COVID fatigue, Chronic fatigue symptoms, Fatigue post viral

Brief summary

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

Detailed description

A total of 30 subjects with post-COVID will be enrolled.

Interventions

BIOLOGICALREGENECYTE®

HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)

Sponsors

StemCyte, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Male or female aged ≥ 18 * With post-COVID condition * Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test) * Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE * Able to provide signed informed consent (by the subject or his/her legally authorized representative) * Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent

Exclusion criteria

* Neurological disorders prior to COVID-19 diagnosis * With pre-existing terminal illness * With known immune disease * Is pregnant or breastfeeding * Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening * Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period * Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases * Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Countries

United States

Contacts

CONTACTClinical Research Department
expandedaccess@stemcyte.com886-2-26013013
CONTACTStemCyte, Inc.
expandedaccess@stemcyte.com866-389-4659

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026